Chemoimmunotherapy for Mesothelioma
Chemoimmunotherapy for Mesothelioma: Pembrolizumab Plus Chemotherapy, 17.3-Month Median Survival, and 2 Pivotal Trials (2026)
Executive Summary
Chemoimmunotherapy is the addition of an immunotherapy drug — the checkpoint inhibitor pembrolizumab (Keytruda) — to standard platinum–pemetrexed chemotherapy as a first-line treatment for advanced pleural mesothelioma. In the phase 3 IND.227 trial, adding pembrolizumab extended median overall survival to 17.3 months versus 16.1 months with chemotherapy alone (hazard ratio 0.79; p=0.0324), with a 3-year overall survival rate of 25% versus 17%. On the strength of that trial, the U.S. Food and Drug Administration approved pembrolizumab plus chemotherapy for previously untreated unresectable pleural mesothelioma in September 2024. A smaller Japanese phase 1b study, KEYNOTE-A17, later reported an objective response rate of 74%, supporting the regimen's activity. Chemoimmunotherapy does not cure mesothelioma — no treatment does — but it is now one of three guideline-recognized first-line options, alongside nivolumab plus ipilimumab and chemotherapy alone. Treatment selection weighs histologic subtype, performance status, and patient preference.
Why This Matters
For a newly diagnosed patient asking "can I get Keytruda with chemotherapy for mesothelioma," the answer since September 2024 is yes — pembrolizumab plus platinum–pemetrexed is an FDA-approved first-line regimen. Understanding what the trials actually showed, who benefits most, and what side effects to expect helps patients and families have an informed conversation with their oncologist. Because these treatments carry substantial cost, documenting every treatment-related expense is also important when families pursue compensation for asbestos exposure through trust funds, U.S. Department of Veterans Affairs benefits, and legal claims.
At a Glance
First-line chemoimmunotherapy for pleural mesothelioma in 2026:
- What it is — the immunotherapy drug pembrolizumab (Keytruda) added to standard platinum–pemetrexed chemotherapy, given together as first-line treatment.
- Pivotal evidence (IND.227) — median overall survival 17.3 versus 16.1 months with chemotherapy alone; hazard ratio 0.79; p=0.0324.[1]
- Durable benefit — 3-year overall survival 25% with pembrolizumab plus chemotherapy versus 17% with chemotherapy alone.[1]
- FDA approval — pembrolizumab plus chemotherapy was approved for previously untreated unresectable pleural mesothelioma in September 2024.[2]
- Confirmatory data (KEYNOTE-A17) — a Japanese phase 1b study reported an objective response rate of 74% with a tolerable safety profile.[3]
- Side effects — grade 3–4 treatment-related adverse events occurred in 27% of the pembrolizumab group versus 15% with chemotherapy alone in IND.227.[1]
- Guideline status — the 2025 ASCO guideline recognizes pembrolizumab plus chemotherapy as one of three first-line systemic regimens for unresectable disease.[2]
- Not a cure — chemoimmunotherapy extends survival and can shrink tumors, but does not eliminate the disease.
Key Facts
| Essential Chemoimmunotherapy Information | |
|---|---|
| Regimen | Pembrolizumab 200 mg every 3 weeks + cisplatin or carboplatin with pemetrexed 500 mg/m² |
| Pivotal Trial | IND.227 / KEYNOTE-483 — phase 3, 440 patients, Canada/Italy/France (NCT02784171) |
| Median Overall Survival (OS) | 17.3 months vs 16.1 months with chemotherapy alone |
| Hazard Ratio (HR) | 0.79 (95% CI 0.64–0.98), p=0.0324 |
| 3-Year Overall Survival | 25% vs 17% with chemotherapy alone |
| FDA Approval | September 2024 (previously untreated unresectable pleural mesothelioma) |
| KEYNOTE-A17 Objective Response Rate (ORR) | 74% (Japanese phase 1b, 19 participants) |
| Guideline Status | One of three first-line regimens in the 2025 ASCO guideline |
What Was First-Line Mesothelioma Treatment Before Chemoimmunotherapy?
For two decades, the standard first-line treatment for advanced pleural mesothelioma was chemotherapy alone — the combination of a platinum drug (cisplatin or carboplatin) with pemetrexed, given every three weeks for up to six cycles. This regimen, established in 2003, improved survival over older chemotherapy but left most patients with a median overall survival in the range of 12 to 16 months. The plateau in chemotherapy outcomes is what motivated researchers to test whether adding immunotherapy could do better. For the full landscape of surgery, radiation, and other systemic options, see mesothelioma treatment options and costs.
What Does "Chemoimmunotherapy" Mean for Mesothelioma?
Chemoimmunotherapy means giving chemotherapy and immunotherapy together rather than one at a time. In this regimen, standard platinum–pemetrexed chemotherapy is combined with pembrolizumab (brand name Keytruda), a checkpoint inhibitor. Chemotherapy works by directly killing rapidly dividing tumor cells, while pembrolizumab blocks the PD-1 pathway that mesothelioma uses to hide from the immune system — releasing the body's own T cells to attack the cancer. The two mechanisms are complementary, which is the rationale for combining them in the first-line setting. Pembrolizumab is given as a 200 mg intravenous infusion every three weeks, alongside the chemotherapy cycles, and may continue for up to two years. For a broader overview of checkpoint inhibitors in this disease, see immunotherapy for mesothelioma.
What Did the IND.227 Trial Show?
The pivotal evidence for first-line chemoimmunotherapy comes from the IND.227 / KEYNOTE-483 trial (Canadian Cancer Trials Group; ClinicalTrials.gov NCT02784171), an open-label phase 3 study conducted at 51 hospitals in Canada, Italy, and France. It randomly assigned 440 patients with previously untreated advanced pleural mesothelioma to chemotherapy alone or chemotherapy plus pembrolizumab.[1][4]
Adding pembrolizumab significantly improved survival: median overall survival was 17.3 months versus 16.1 months with chemotherapy alone (hazard ratio for death 0.79; 95% CI 0.64–0.98; two-sided p=0.0324). The 3-year overall survival rate was 25% with pembrolizumab plus chemotherapy versus 17% with chemotherapy alone.[1] On the basis of these results, the U.S. Food and Drug Administration approved pembrolizumab in combination with chemotherapy for previously untreated unresectable pleural mesothelioma in September 2024.[2] These outcome figures are consistent with the write-up on the treatment options page, which covers the same trial in the context of the full first-line landscape.
What Did the KEYNOTE-A17 Trial Confirm?
KEYNOTE-A17 (NCT04153565) was a separate, smaller phase 1b study of first-line pembrolizumab plus cisplatin–pemetrexed in Japanese participants with advanced pleural mesothelioma. Among 19 participants, the objective response rate (ORR) was 74% — all partial responses — with a median duration of response (DoR) of 16.8 months. The study's primary purpose was to assess tolerability, and the regimen was considered tolerable based on a low rate of dose-limiting toxicities.[3]
Because KEYNOTE-A17 enrolled only 19 patients and was designed as a safety and tolerability study — not a survival comparison — it should be read as supporting, confirmatory evidence rather than the pivotal trial. Its value is showing consistent antitumor activity of the chemoimmunotherapy regimen in a different patient population. The pivotal survival evidence remains IND.227.
Who Is Eligible for Chemoimmunotherapy?
First-line pembrolizumab plus chemotherapy is intended for patients with previously untreated, unresectable (inoperable) advanced pleural mesothelioma and reasonably preserved performance status. Histologic subtype is an important consideration in treatment selection. Guideline discussion and clinical experience suggest that epithelioid mesothelioma may benefit particularly from pembrolizumab plus chemotherapy, while non-epithelioid (sarcomatoid and biphasic) subtypes show pronounced responses to the alternative first-line regimen of nivolumab plus ipilimumab. Because the two immunotherapy strategies have different strengths, treatment selection should weigh histologic subtype, performance status, and patient preference in consultation with a mesothelioma specialist. The 2025 ASCO guideline provides the formal framework for these choices.[2]
What Side Effects Should Patients Expect?
Adding immunotherapy to chemotherapy increases the rate of serious side effects. In IND.227, grade 3–4 treatment-related adverse events (AEs) occurred in 27% of patients in the pembrolizumab group versus 15% of patients receiving chemotherapy alone.[1] Beyond the usual chemotherapy effects such as fatigue, nausea, and low blood counts, checkpoint inhibitors like pembrolizumab can cause immune-related adverse events — the immune system attacking healthy tissue, which can affect the skin, thyroid, colon, lungs, or liver. Most immune-related effects are manageable when caught early, which is why patients on chemoimmunotherapy are monitored closely throughout treatment. Patients should report new or worsening symptoms promptly so that side effects can be addressed before they become severe.
How Should You Discuss Chemoimmunotherapy With Your Oncologist?
If you or a family member has been newly diagnosed with pleural mesothelioma, it is reasonable to ask your oncologist whether first-line pembrolizumab plus chemotherapy is appropriate for your situation. Helpful questions include: Is my mesothelioma epithelioid or non-epithelioid, and how does that affect the choice between chemoimmunotherapy and nivolumab plus ipilimumab? Am I a candidate for surgery in addition to systemic therapy? Would a clinical trial offer an additional option? Seeking care at a specialized mesothelioma center — or a second opinion from one — can help ensure the treatment plan reflects the latest evidence. Patients researching active studies can review the mesothelioma clinical trials overview.
Because mesothelioma treatment is costly, families are encouraged to document all treatment-related expenses. Compensation for these costs may be available through asbestos trust funds, VA benefits, and legal claims against the manufacturers responsible for the asbestos exposure. Families researching their options can consult a mesothelioma law firm such as Danziger & De Llano to understand which compensation channels apply to their circumstances.
Frequently Asked Questions
Can you get Keytruda with chemotherapy for mesothelioma?
Yes. Since September 2024, the FDA has approved pembrolizumab (Keytruda) in combination with platinum–pemetrexed chemotherapy as a first-line treatment for previously untreated, unresectable pleural mesothelioma. This chemoimmunotherapy regimen extended median overall survival to 17.3 months versus 16.1 months with chemotherapy alone in the phase 3 IND.227 trial.[1][2]
How much does pembrolizumab plus chemotherapy improve survival in mesothelioma?
In the IND.227 phase 3 trial, adding pembrolizumab to chemotherapy improved median overall survival from 16.1 to 17.3 months (hazard ratio 0.79; p=0.0324) and raised the 3-year overall survival rate from 17% to 25%. The benefit is meaningful but modest, and chemoimmunotherapy does not cure the disease.[1]
Is chemoimmunotherapy the same as nivolumab plus ipilimumab for mesothelioma?
No. Chemoimmunotherapy combines one immunotherapy drug (pembrolizumab) with chemotherapy. Nivolumab plus ipilimumab is a separate, chemotherapy-free regimen combining two immunotherapy drugs. Both are FDA-approved first-line options; the choice depends on factors including histologic subtype, with non-epithelioid subtypes often favored toward nivolumab plus ipilimumab.[2]
See Also
- Mesothelioma Treatment Options and Costs
- Immunotherapy for Mesothelioma
- Mesothelioma Clinical Trials
- Pleural Mesothelioma
- Mesothelioma Treatment
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. PMID 37931632.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006-1038. PMID 39778125.
- ↑ 3.0 3.1 Kijima T, Kato T, Goto Y, Kuribayashi K, Mikami K, Negi Y, et al. KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. Cancer Science. 2025;116(8):2208-2217. PMID 40407381.
- ↑ ClinicalTrials.gov. A Study of Pembrolizumab in Combination With Chemotherapy for Advanced Pleural Mesothelioma (IND.227 / KEYNOTE-483, NCT02784171). Canadian Cancer Trials Group.